Daiichi Sankyo Co Ltd
TSE:4568

Watchlist Manager
Daiichi Sankyo Co Ltd Logo
Daiichi Sankyo Co Ltd
TSE:4568
Watchlist
Price: 4 435 JPY -1.49% Market Closed
Market Cap: 8.4T JPY
Have any thoughts about
Daiichi Sankyo Co Ltd?
Write Note

Daiichi Sankyo Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Daiichi Sankyo Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Daiichi Sankyo Co Ltd
TSE:4568
Short-Term Investments
ÂĄ140.8B
CAGR 3-Years
-14%
CAGR 5-Years
-23%
CAGR 10-Years
-6%
Takeda Pharmaceutical Co Ltd
TSE:4502
Short-Term Investments
ÂĄ47.2B
CAGR 3-Years
22%
CAGR 5-Years
28%
CAGR 10-Years
-11%
Otsuka Holdings Co Ltd
TSE:4578
Short-Term Investments
ÂĄ91.1B
CAGR 3-Years
54%
CAGR 5-Years
5%
CAGR 10-Years
-6%
S
Shionogi & Co Ltd
TSE:4507
Short-Term Investments
ÂĄ272.5B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
17%
Chugai Pharmaceutical Co Ltd
TSE:4519
Short-Term Investments
ÂĄ301.7B
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
10%
Astellas Pharma Inc
TSE:4503
Short-Term Investments
ÂĄ35.7B
CAGR 3-Years
106%
CAGR 5-Years
55%
CAGR 10-Years
1%
No Stocks Found

Daiichi Sankyo Co Ltd
Glance View

Market Cap
8.4T JPY
Industry
Pharmaceuticals

Daiichi Sankyo Co., Ltd., a prominent player in the global pharmaceuticals sector, has cemented its position as a leader through innovation and strategic expansion. Founded in 2005 from the merger of Daiichi Pharmaceutical and Sankyo Company, the company has continually focused on research and development, particularly in the fields of oncology, cardiovascular medicine, and vaccines. This dedication has resulted in a robust pipeline of transformative therapies, including the highly anticipated antibody-drug conjugates that address unmet medical needs. Investors are drawn to Daiichi Sankyo not just for its impressive portfolio but also for its commitment to quality and sustainability, underpinned by a strong financial foundation that supports ongoing growth. As the global healthcare landscape evolves, Daiichi Sankyo is well-prepared to adapt and capitalize on emerging opportunities, such as the accelerating demand for personalized medicine and innovative treatment modalities. The company's strategic partnerships and collaborations, particularly with international giants, have further bolstered its reach and resource capacity, making it a formidable force in the industry. For investors, this dynamic blend of innovative prowess, strategic foresight, and sound financial management makes Daiichi Sankyo an attractive option, promising potential long-term growth as it continues to push the boundaries of what's possible in healthcare.

Intrinsic Value
5 494.59 JPY
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Daiichi Sankyo Co Ltd's Short-Term Investments?
Short-Term Investments
140.8B JPY

Based on the financial report for Sep 30, 2024, Daiichi Sankyo Co Ltd's Short-Term Investments amounts to 140.8B JPY.

What is Daiichi Sankyo Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
-6%

Over the last year, the Short-Term Investments growth was 82%. The average annual Short-Term Investments growth rates for Daiichi Sankyo Co Ltd have been -14% over the past three years , -23% over the past five years , and -6% over the past ten years .

Back to Top